Thomas Shrader
Stock Analyst
(1.68)
# 2,191
Out of 4,648 analysts
42
Total ratings
40%
Success rate
-2.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Shrader
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATHA Athira Pharma | Downgrades: Neutral | n/a | $0.64 | - | 3 | Sep 4, 2024 | |
| PCVX Vaxcyte | Maintains: Buy | $98 → $160 | $106.49 | +50.25% | 2 | Sep 3, 2024 | |
| OVID Ovid Therapeutics | Maintains: Buy | $11 → $5 | $1.18 | +323.73% | 2 | Jun 18, 2024 | |
| ACIU AC Immune | Initiates: Buy | $8 | $2.94 | +172.11% | 1 | May 31, 2024 | |
| PMN ProMIS Neurosciences | Initiates: Buy | $8 | $1.08 | +640.74% | 1 | Oct 3, 2023 | |
| DTIL Precision BioSciences | Maintains: Buy | $180 → $60 | $8.29 | +623.76% | 1 | Jul 28, 2023 | |
| BHVN Biohaven | Reiterates: Buy | $24 | $50.04 | -52.04% | 2 | Jun 6, 2023 | |
| ANNX Annexon | Maintains: Buy | $15 → $7 | $7.09 | -1.27% | 2 | May 25, 2023 | |
| COYA Coya Therapeutics | Initiates: Buy | $15 | $6.85 | +118.98% | 1 | May 18, 2023 | |
| BCAB BioAtla | Maintains: Buy | $68 → $13 | $2.00 | +550.00% | 3 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $31 | $38.15 | -18.74% | 3 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $16 | $5.27 | +203.61% | 1 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $10 | $2.07 | +383.09% | 2 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $22 | $2.95 | +645.76% | 2 | Oct 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $14 | $6.25 | +124.00% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $14.49 | +251.97% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $2.29 | +598.69% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.65 | - | 1 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $27.21 | - | 2 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.24 | - | 1 | Sep 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $58 | $9.29 | +524.33% | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $4.25 | -29.41% | 3 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $397 → $346 | $173.52 | +99.40% | 3 | Feb 21, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.70 | - | 1 | Jun 30, 2017 |
Athira Pharma
Sep 4, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.64
Upside: -
Vaxcyte
Sep 3, 2024
Maintains: Buy
Price Target: $98 → $160
Current: $106.49
Upside: +50.25%
Ovid Therapeutics
Jun 18, 2024
Maintains: Buy
Price Target: $11 → $5
Current: $1.18
Upside: +323.73%
AC Immune
May 31, 2024
Initiates: Buy
Price Target: $8
Current: $2.94
Upside: +172.11%
ProMIS Neurosciences
Oct 3, 2023
Initiates: Buy
Price Target: $8
Current: $1.08
Upside: +640.74%
Precision BioSciences
Jul 28, 2023
Maintains: Buy
Price Target: $180 → $60
Current: $8.29
Upside: +623.76%
Biohaven
Jun 6, 2023
Reiterates: Buy
Price Target: $24
Current: $50.04
Upside: -52.04%
Annexon
May 25, 2023
Maintains: Buy
Price Target: $15 → $7
Current: $7.09
Upside: -1.27%
Coya Therapeutics
May 18, 2023
Initiates: Buy
Price Target: $15
Current: $6.85
Upside: +118.98%
BioAtla
Mar 28, 2023
Maintains: Buy
Price Target: $68 → $13
Current: $2.00
Upside: +550.00%
Mar 20, 2023
Maintains: Buy
Price Target: $26 → $31
Current: $38.15
Upside: -18.74%
Mar 2, 2023
Maintains: Buy
Price Target: $54 → $16
Current: $5.27
Upside: +203.61%
Nov 14, 2022
Maintains: Buy
Price Target: $30 → $10
Current: $2.07
Upside: +383.09%
Oct 5, 2022
Maintains: Buy
Price Target: $15 → $22
Current: $2.95
Upside: +645.76%
May 24, 2022
Maintains: Buy
Price Target: $31 → $14
Current: $6.25
Upside: +124.00%
Apr 20, 2021
Initiates: Buy
Price Target: $51
Current: $14.49
Upside: +251.97%
Mar 8, 2021
Initiates: Buy
Price Target: $16
Current: $2.29
Upside: +598.69%
Feb 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $6.65
Upside: -
Oct 16, 2020
Downgrades: Neutral
Price Target: n/a
Current: $27.21
Upside: -
Sep 23, 2020
Downgrades: Neutral
Price Target: n/a
Current: $3.24
Upside: -
Sep 15, 2020
Maintains: Buy
Price Target: $51 → $58
Current: $9.29
Upside: +524.33%
Apr 3, 2020
Maintains: Buy
Price Target: $4 → $3
Current: $4.25
Upside: -29.41%
Feb 21, 2019
Downgrades: Hold
Price Target: $397 → $346
Current: $173.52
Upside: +99.40%
Jun 30, 2017
Downgrades: Hold
Price Target: n/a
Current: $0.70
Upside: -